| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development | ||||||
9,738 | 4,368 | 4,756 | 2,654 | 1,506 | 547 | 992 |
General and administrative | ||||||
24,810 | 12,881 | 8,138 | 8,499 | 10,526 | 7,304 | 5,229 |
Depreciation and amortization | ||||||
54 | 12 | - | - | - | - | - |
Depreciation | ||||||
- | - | 11 | 10 | 10 | 15 | 17 |
Total operating expenses | ||||||
34,603 | 17,262 | 12,906 | 11,164 | 12,044 | 7,868 | 6,238 |
Loss from operations | ||||||
-34,603 | -17,262 | -12,906 | -11,164 | -12,044 | -7,868 | -6,238 |
Other income (expense): | ||||||
Gain on change in fair value of derivatives | ||||||
- | - | 210 | -422 | 3,113 | 0 | - |
Interest income, net | ||||||
132 | 10 | 0 | 0 | -1 | -11 | -70 |
Gain on disposal of assets | ||||||
0 | 0 | - | - | - | - | - |
Financing costs | ||||||
- | - | - | - | 529 | - | - |
Financing costs | ||||||
- | - | - | - | - | 593 | 3,496 |
Total other income (expense) | ||||||
- | - | - | - | 2,582 | -604 | - |
Loss before income taxes | ||||||
-34,470 | -17,251 | -12,695 | -11,587 | -9,461 | -8,473 | -9,804 |
Income taxes (benefit) | ||||||
0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net loss | ||||||
-34,470 | -17,251 | - | - | - | - | - |
Preferred stock dividend | ||||||
25 | 884 | 119 | 110 | 351 | 300 | 297 |
Net loss attributable to common stockholders | ||||||
-34,495 | -18,136 | -12,815 | -11,697 | -9,812 | -8,773 | -10,101 |
Non-controlling interest | ||||||
415 | 0 | - | - | - | - | - |
NET LOSS ATTRIBUTABLE TO BIOSIG TECHNOLOGIES, INC. | ||||||
-34,079 | -18,136 | -12,695 | -11,587 | -9,461 | -8,473 | -9,804 |
Net loss per common share, basic and diluted (in Dollars per share) | ||||||
-1.65 | -1.25 | -1.25 | -0.60 | -0.70 | -0.91 | -1.23 |
Weighted average number of common shares outstanding, basic and diluted (in Shares) | ||||||
20,694 | 14,504 | 10,220 | 19,490 | 14,103 | 9,650 | 8,187 |